Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125919372 | 12591937 | 2 | F | 201607 | 20160902 | 20160726 | 20160906 | EXP | PHHY2016DE101216 | NOVARTIS | 0.00 | A | F | Y | 74.00000 | KG | 20160906 | CN | COUNTRY NOT SPECIFIED | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125919372 | 12591937 | 1 | PS | TASIGNA | NILOTINIB | 1 | Unknown | 150 MG, QID (4 TABLETS DAILY) 2X150 MG TASIGNA IN THE MORNING AND 2X150 MG TASIGNA IN THE EVENING | 22068 | 150 | MG | CAPSULE | QID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125919372 | 12591937 | 1 | Chronic myeloid leukaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125919372 | 12591937 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125919372 | 12591937 | Anxiety | |
| 125919372 | 12591937 | Dyspnoea | |
| 125919372 | 12591937 | Feeling abnormal | |
| 125919372 | 12591937 | Headache | |
| 125919372 | 12591937 | Nausea |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125919372 | 12591937 | 1 | 201504 | 0 |